Enhanced Genomics is redefining how medicines are discovered by revealing the causal biology behind genetic variation. Our integrated 3D multi-omics platform enables the rapid identification of high-confidence therapeutic targets for common diseases.
Location: United Kingdom
Total raised: $19M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.09.2025 | Series A | $19M | Parkwalk A... |
Mentions in press and media 5
| Date | Title | Description |
| 23.09.2025 | Enhanced Genomics: $19 Million Series A Raised For Advancing Development Of Therapeutics Pipeline | Enhanced Genomics is a biotechnology company that is making significant strides in the realm of drug development through its innovative use of 3D multi-omics technology. Recently, the company announced that it has completed a new financing ... |
| 22.09.2025 | Enhanced Genomics Secures $19M for Breakthrough Drug Discovery | Enhanced Genomics, a pioneering UK biotechnology company, recently secured a significant extension to its Series A funding, now totaling USD $19 million. This capital injection propels its mission to revolutionize drug discovery for common,... |
| 17.09.2025 | Enhanced Genomics Extends Series A Funding to USD $19M | Enhanced Genomics, a Cambridge, UK-based biotechnology company developing 3D multi-omics to identify genetically validated drug targets for common diseases, extended its Series A funding to USD$19M. Backers included BGF, Parkwalk and Meltwi... |
| 16.09.2025 | Cambridge’s Enhanced Genomics extends funding to €16 million to drive development of therapeutics pipeline | Enhanced Genomics, a British BioTech company innovating 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced it has completed a financing round, extending its total Seri... |
| 16.09.2025 | Enhanced Genomics extends Series A funding to USD $19 million to drive development of therapeutics pipeline | Enhanced’s 3D multi-omics platform delivers genetically validated targets for common diseases, accelerating development and increases rates of success in high-value indications Funding from BGF, Parkwalk and Meltwind to drive therapeutics d... |